Pediatric onset multiple sclerosis in Kuwait

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Clinical Neurology and Neurosurgery Pub Date : 2024-11-16 DOI:10.1016/j.clineuro.2024.108643

Raed Alroughani , Malak AlMojel , Dalal Qasem , Jasem Al-Hashel , Samar Farouk Ahmed

{"title":"Pediatric onset multiple sclerosis in Kuwait","authors":"Raed Alroughani , Malak AlMojel , Dalal Qasem , Jasem Al-Hashel , Samar Farouk Ahmed","doi":"10.1016/j.clineuro.2024.108643","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Epidemiological data of pediatric-onset multiple sclerosis (POMS) in the Middle East is limited.</div></div><div><h3>Objective</h3><div>To determine the demographic and clinical characteristics of POMS in Kuwait.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted to assess the clinical characteristics of multiple sclerosis (MS) patients who disease onset started at age < 18 years and fulfilled the International Pediatric MS Study Group (IPMSSG) criteria for MS.</div></div><div><h3>Results</h3><div>Of 249 POMS who were assessed, 70.3 % were female. The mean age at onset was 15.06 <u>+</u>11.78 years. Brainstem / cerebellar manifestation (34.9 %) were the most frequent presentation at onset of disease, followed by spinal (29.3 %) and visual pathway (27.3 %) symptoms. At the last follow-up visits, most of the patients (83.5 %) remained in a relapsing-remitting phenotype. The annual relapse rate (ARR) was 0.18 throughout the first 2 years while on treatment. At the baseline visit, the 51.4 % of the cohort-initiated platform therapies. Breakthrough disease (36.1 %) and adverse events (9.6 %) were the most common indications to escalate or switch to other disease-modifying drugs (DMTs).</div></div><div><h3>Conclusion</h3><div>Most POMS patients continued to be in a relapsing phenotype in our longitudinal study. Disease breakthrough is common in POMS especially when using platform therapies.</div></div>","PeriodicalId":10385,"journal":{"name":"Clinical Neurology and Neurosurgery","volume":"248 ","pages":"Article 108643"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neurology and Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0303846724005304","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Epidemiological data of pediatric-onset multiple sclerosis (POMS) in the Middle East is limited.

Objective

To determine the demographic and clinical characteristics of POMS in Kuwait.

Methods

A retrospective study was conducted to assess the clinical characteristics of multiple sclerosis (MS) patients who disease onset started at age < 18 years and fulfilled the International Pediatric MS Study Group (IPMSSG) criteria for MS.

Results

Of 249 POMS who were assessed, 70.3 % were female. The mean age at onset was 15.06 +11.78 years. Brainstem / cerebellar manifestation (34.9 %) were the most frequent presentation at onset of disease, followed by spinal (29.3 %) and visual pathway (27.3 %) symptoms. At the last follow-up visits, most of the patients (83.5 %) remained in a relapsing-remitting phenotype. The annual relapse rate (ARR) was 0.18 throughout the first 2 years while on treatment. At the baseline visit, the 51.4 % of the cohort-initiated platform therapies. Breakthrough disease (36.1 %) and adverse events (9.6 %) were the most common indications to escalate or switch to other disease-modifying drugs (DMTs).

Conclusion

Most POMS patients continued to be in a relapsing phenotype in our longitudinal study. Disease breakthrough is common in POMS especially when using platform therapies.

查看原文本刊更多论文

科威特小儿多发性硬化症。

背景：中东地区小儿多发性硬化症（POMS）的流行病学数据有限：中东地区小儿多发性硬化症（POMS）的流行病学数据有限：确定科威特多发性硬化症患者的人口统计学和临床特征：方法：开展一项回顾性研究，评估发病年龄小于18岁、符合国际儿科多发性硬化症研究小组（IPMSSG）多发性硬化症标准的多发性硬化症（MS）患者的临床特征：在接受评估的249名多发性硬化症患者中，70.3%为女性。平均发病年龄为15.06 +11.78岁。脑干/小脑表现（34.9%）是发病时最常见的症状，其次是脊柱（29.3%）和视觉通路（27.3%）症状。在最后一次随访中，大多数患者（83.5%）仍处于复发-缓解表型。在接受治疗的头两年中，年复发率（ARR）为 0.18。在基线访视时，51.4%的患者启动了平台疗法。突破性疾病（36.1%）和不良反应（9.6%）是升级或改用其他改变病情药物（DMTs）的最常见指征：结论：在我们的纵向研究中，大多数POMS患者仍处于复发表型。结论：在我们的纵向研究中，大多数POMS患者仍处于复发表型，疾病突破在POMS患者中很常见，尤其是在使用平台疗法时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Neurology and Neurosurgery 医学-临床神经学

CiteScore

3.70

自引率

5.30%

发文量

358

审稿时长

46 days

期刊介绍： Clinical Neurology and Neurosurgery is devoted to publishing papers and reports on the clinical aspects of neurology and neurosurgery. It is an international forum for papers of high scientific standard that are of interest to Neurologists and Neurosurgeons world-wide.